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Summary The main objective of phase II clinical trials is to estimate treatment efficacy on a relatively small
number of patients in order to decide whether the treatment ought to be studied in large-scale comparative
trials. They play a key role in the drug development process, since the results determine whether or not to
proceed to phase III trials. Multistage designs for phase II clinical trials proposed by Gehan, Fleming, Simon
and Ensign are described and compared. Gehan's and Simon's designs have two stages, Fleming's designs can
have two or more stages, and Ensign's three-stage design combines the first stage of Gehan with the two stages
of Simon. Phase II clinical trial protocols and reports should include a description of the design selected with a
justification for the particular choice. The present practice is very far from this ideal.
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Testing a new treatment on humans requires care, time and
resources, and decisions concerning the future of the new
treatment are made at the end ofeach phase I, II or III of the
drug development process. A treatment can be abandoned at
any stage of its development. The objective of a phase I trial
is to determine a maximum tolerated dose, safe for a phase II
study of therapeutic activity. Toxicity is therefore the main
end point in a phase I trial. The phase II evaluation of a new
anti-cancer drug is a screen to determine whether the drug
has anti-tumour activity worthy of future clinical evaluation.
The main end point is tumour response, completed by
monitoring of toxicity data. A typical phase II study includes
less than 50 patients, the objective being to identify an active
treatment or to reject an inactive treatment as soon as
possible. Phase II clinical trials play a key role in the
development of a treatment because the results determine
whether or not to proceed with phase III trials. Phase III
randomised trials study the efficacy of a new treatment in the
clinical context, and the end points are generally survival and
disease-free survival. They include a much larger number of
patients than phase II studies, from a few hundred in rare
diseases to several thousand if not ten thousand in more
frequent cancer sites. One must therefore be sufficiently
convinced of the activity of a treatment to decide whether or
not it should be tested in a phase III randomised trial.
To determine the number ofpatients required for a phase II
trial, different multistage designs have been developed. The first
design was proposed by Gehan in 1961 and is still being widely
used (Gehan, 1961), although rarely cited. It is a two-stage
design which allows for the rapid rejection of an ineffective
treatment at the end of the first stage, and provides an
estimation ofthe success rate with a given precision, at the end
of the second stage. Fleming (1982) developed multistage
designs which enable early termination of a trial when the
treatment is either clearly effective or clearly ineffective. Simon
(1989) improved Fleming's two-stage design by minimising
either the average or the maximum number ofpatients required
under the hypothesis of treatment ineffectiveness. Recently,
Ensign et al. (1994) developed a three-stage design which
integrates Gehan's and Simon's designs. Each ofthese designs
is subject to different constraints and the aim ofthis paper is to
present the designs and discuss their advantages and
disadvantages.
General prinicples
The response to a treatment will be summarised as being a
success or a failure. In oncology, a success is usually defined
as either a complete response or as an objective response
which also includes partial responses.
The therapeutic efficacy is evaluated by the parameter ir,
the true proportion of successes among a given population. If
this true proportion of successes is less than or equal to a
predetermined value po, which we shall call the maximal rate
of inefficacy, the efficacy of the treatment will be considered
as insufficient. If the true proportion of successes is greater
than or equal to a predetermined value pi, which we shall call
the minimal rate of efficacy, the treatment will be considered
as being sufficiently effective for further study in phase III
trials.
Most statistical methods developed for the inclusion of
patients in phase II trials are built in at least two stages. In
the simplest case, n, patients are included in the first stage
and r, successes are observed. Depending on the value of
ri, either the trial is stopped or recruitment continues by
accruing a further n2 patients into a second stage, among
whom r2 successes are observed. The cumulative number of
successes is then R2=r,+r2 out of n1 +n2 patients.
At each stage k, a decision for stopping the trial or
continuing to accrue patients is taken depending on the
observed cumulative number of successes Rk. The general
procedure at each stage k is as follows:
* If the total number of successes Rk is less than a
predetermined value, which we shall call the lower cut-
off point of decision making, then the treatment is not
considered to be sufficiently effective. The hypothesis of
efficacy is then rejected. The error risk flk associated with
this decision (type II error) is the probability of rejecting
efficacy at the end of stage k when in fact the treatment
leads to a success rate at least equal to Pi
* If the total number of successes Rk is greater than or equal
to a predetermined value, which we shall call the upper
cut-off point of decision making, then the treatment is
considered sufficiently effective for further study in phase
III trial. The hypothesis of inefficacy is thus rejected. The
error risk ak associated with this decision (type I error) is
the probability of concluding in favour of efficacy at the
end of stage k when, in fact, the treatment is ineffective,
i.e. when the success rate is po or less.
* If the total number of successes is between the lower and
the upper cut-off points, the trial continues and proceeds
to the next stage by including more patients.
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At the end of the last stage, there is a single cut-off point. If
the total number of successes is at least equal to this cut-off
point, one concludes in favour of efficacy, if the total number
of successes is below the cut-off point, one concludes the
ineffectiveness of the treatment.
The error risks ak and 13k associated with a wrong
conclusion at each stage for each hypothesis are computed
from binomial distributions, as are the overall error rates ax
and ft.
Different designs
Gehan's design
Gehan (1961) proposed a design which rejects an ineffective
treatment early when no success is observed among the first
n1 patients. Here n, is obtained from the following equation:
tI=Probability (O successes among nI patients given P1)
(I _P )n
This equation states that the probability of rejecting a
treatment which has a true proportion of successes equal to
Pi, after n1 consecutive failures, is equal to fi. For example, if
ft'
- 0.05 and pi =0.30, we find n1 =9 patients, since the
probability of observing nine consecutive failures, if the true
percentage of success is 30%, equals (1- 0.30)9= 0.040 which
is slightly less than 0.05.
If no successes are observed at the first stage, the trial stops
and the treatment is considered ineffective with a ,Il error rate
of 4%. A conclusion of efficacy, however, cannot be reached
at the end ofthis first stage, no matter how many successes are
observed, and therefore the risk a, is taken to be 0.
If there is at least one success, the trial proceeds to the
second stage. The goal of this second stage is to estimate the
true proportion of successes 7t with a given precision. The
precision is defined as the estimated standard error of 7.
Tables giving the sample sizes for each stage are provided in
Gehan's paper for several values of pl, for 5I =5% or 10%
and for precisions of 5% and 10%. These tables are also
provided in a recent book (Machin et al., 1996). The size of
the second stage varies greatly, varying for instance, after
the inclusion of nine patients, between 71 and 91 depending
on the number of successes observed during the first stage,
for a precision of 5%. For pl=0.20 and ft,=5%, which
were the values used by Gehan in his original paper, one
gets n1 = 14. This particular result, n, = 14, is often quoted
without any mention of the underlying hypothesis, but with
reference to Gehan's paper.
Gehan's design is different from the designs presented
below because it considers the sample size problem from an
estimation point of view, while controlling the risk ,B of
rejecting an effective treatment. There is no need to specify a
value Po of minimal efficacy, which would be used for
controlling the probability a of accepting an ineffective
treatment. The other designs presented here determine
sample size and rejection regions, while controlling for both
cx and ,B error rates. These designs do not consider the
problem of estimation.
Fleming's designs
Fleming (1982) developed designs with two or three stages.
These designs allow an early termination ofthe trial when the
intermediate results are extreme, either in favour of the
efficacy or of the inefficacy of the treatment. In a first step,
the total number of patients is estimated as if one was
planning a single-stage trial with error rates a and ft for
success rates respectively larger than Pi and smaller than po.
The number of stages is then selected arbitrarily, usually
between two and three, and the total number of patients is
divided arbitrarily, in general equally, between the stages. In
the last step, the cut-off points are defined by the required
values for a and ft.
Simon's designs
Simon (1989) proposed two designs, each with two stages.
Simon's Optimum design minimises the average number of
patients exposed to an ineffective treatment and his Minimax
design minimises the maximum sample size required. In these
designs, the number of patients in each stage is not specified
by the investigator, unlike Fleming's design, but is a result of
the minimisation constraint.
In Simon's original proposal, early termination of the trial
was considered possible only when the results supported the
hypothesis of treatment inefficacy. The calculations presented
here use a modification of Simon's designs where one stops
the trial at the end of the first stage if the accumulated
number of successes reaches the upper cut-off point of the
second stage. A conclusion in favour of efficacy is then
reached at the end of the first stage.
Ensign's design
Ensign et al. (1994) proposed a three-stage design which
combines Gehan's first stage with Simon's Optimum two-
stage design. It allows early termination of a trial beginning
with a long run of failures. The first stage is thus constructed
as Gehan's first stage: n, patients are treated and if no
successes are observed, the trial is stopped. If at least one
success is observed among the first n1 patients, then the two-
stage Simon's Optimum design is used.
Comparision of designs
We have compared the designs, using typical error rates of
a=0.05 and f=0.10. The treatment was considered as not
sufficiently effective if the true proportion of successes was
less than or equal to po = 10%. If the true proportion of
successes was greater than or equal to p, =30%, the
treatment was considered as worthy of study in a phase III
trial. These proportions, po and p' are symmetrical around
20%, a success rate frequently used in phase II oncology
trials which study one treatment.
In principle, Gehan's design cannot be compared with the
other designs since it specifies the error rate ft' but does not
specify the error rate a. In order to guarantee an overall # error
rate of 10%, we have chosen a design which satisfies Gehan's
constraint of ft' =5%. This leads to the inclusion of nine
patients in the first step. The total number ofpatients equal to
35 has been selected according to Fleming's design (see below).
This leads to an overall ft error of9% forPi =30%.
Table I presents, for each design, the number of stages, the
cut-off points and the sample size. It also includes the
probabilities of early termination (PET) and the average
sample sizes (AN) under the hypotheses of inefficacy
(po= 10%) and of efficacy (p, =30%).
To show how Table I should be read, we consider
Fleming's design. The total sample size is 35 patients, which
is the number of patients required in a single-stage design
with a=5% and ft below 10%. The division of the 35
patients between the two stages in arbitrary, and we have
chosen the sample sizes used by Fleming (1982), i.e. 20
patients for the first stage and 15 for the second stage. At the
end of the first stage, if the number of successes is less than
three, the trial is stopped and the treatment is judged not
sufficiently effective. If six or more successes are observed, the
trial is stopped and the treatment is judged effective enough
for further study in a phase III trial. If three, four or five
successes are observed, 15 more patients are recruited into the
study. Once these 15 patients are included, if the total
number of successes observed in the 35 patients is less than
seven, the treatment is concluded to be ineffective. If the
number of successes is at least seven, it is concluded to be
effective. With this particular design, the overall error rate a
is equal to 0.053, which is quite close to the nominal level of
5%, and the overall error rate # is equal to 0.080, which isPhase 11 clinical trial designs
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Table I Comparison of sample size, cut-off points, probability of early termination (PET) and average sample size (AN) for five phase II
designs, with a-0.05 and ,3-0.10
Number
ofstages
Two
Sample
size at
Stage k stage k
9
26
2
Conclude Conclude
Cumulative ineffectiveness effectiveness
sample size if Rk if Rk
9
35
=0 7
,<6 >,7
Po=10%
PET
39%
p, =30%
AN PET
5%
24.9
1 20 20 <2 >6
2 15 35 6 7
Simon's
Optimum Two
Two
Three
1 18 18
2 17 35
1 22 22
2 11 33
2
3
9
13
23
R is the cumulative number of successes at the end of stage k. 'Including the probability of termination at the end of stage 1.
reasonably close to 10%. If the treatment has a true efficacy
of 10%, the average number of patients (AN) is 24.7 and the
probability of early termination (PET) after the first stage is
69%. This PET is the sum of the probability of early
termination with a correct conclusion of inefficacy (68%) and
of the probability a, of early termination with a wrong
conclusion of efficacy (1%). If the treatment has a true
efficacy of 30%, the average number of patients is 25.7 and
the probability of early termination after the first stage is
62%. This PET is the sum of the probability of early
termination with a correct conclusion of efficacy (58%) and
of the probability fl3 of early termination with a wrong
conclusion of inefficacy (4%).
Comparing the different designs, one can seen that the
maximal sample size varies from 33 for Simon's Minimax
design to 45 patients for Ensign's design. The number of
patients included in the first stage varies from nine for Gehan's
and Ensign's designs to 22 for Simon's Minimax design.
After the first stage, Ensign's design, like Gehan's design,
always stops with a conclusion of inefficacy if no successes
are observed; the other designs stop with a conclusion of
inefficacy if fewer than three successes are observed.
Under the hypothesis of inefficacy, Ensign's design and
Simon's Optimum design have the largest overall probabil-
ities of early termination of the trial (84% and 74%). Among
the designs presented in Table I, Gehan's and Ensign's design
have the smallest probability of early termination at the end
of the first stage. In general, a larger probability of early
termination corresponds to a smaller average sample size.
Under the hypothesis of efficacy, Fleming's design leads to
the highest probability of early termination and to the
smallest average sample size followed by Simon's Minimax
design, Simon's Optimum design, Gehan's design and
Ensign's design.
We have studied the robustness of the ranking of the five
designs to variations of oa, /, po and Pi, considering all nine
combinations of the selection of either o=5%, ,B= 10%, or
a=5%, /=5%, or a=10%, ,B=10%, and the selection of
either p0= 10%, pi=30%, or po=20%, p,=40%, or
po 30%, p, 50%. In general, under the hypothesis of
inefficacy, Ensign's design had the largest overall probability
of early termination, followed by Simon's Optimum design,
Fleming's design and Simon's Minimax design; Gehan's
design having the smallest probability of early termination.
Under the hypothesis of efficacy, the largest probability of
early termination was obtained with Fleming's design,
followed by Ensign's design, Simon's Minimum and Simon's
Optimum designs; Gehan's design corresponding to the
smallest probability of early termination.
Literature review
We have analysed 3 -10 issues published between January
and November 1995 of five journals: American Journal of
Clinical Oncology, British Journal of Cancer, Cancer,
European Journal of Cancer and Journal of Clinical
Oncology, searching for chemotherapy trials in oncology
that were either described as 'phase II' anywhere in the text,
or had tumour response for main end point (these trials being
sometimes described as 'pilot studies').
A total of 83 papers reporting phase II studies as defined
above, were identified: 26 in the American Journal of Clinical
Oncology, 18 in the European Journal of Cancer, 14 in the
Journal of Clinical Oncology, 13 in Cancer and 12 in the
British Journal of Cancer.
Out of these 83 papers, ten (12%) included at least some
information on the statistical technique used: four reported
using Gehan's design, one Fleming's design, two Simon's
design, one an 'optimal restricted Bayes sampling', the last
two specified po and the planned total number of patients,
without specifying the number of stages, one specifying also
the values of a, /3, and p,. The other 73 papers did not specify
any of the following: name of statistical method, number of
stages, oc, /3, po and p,. Among these 73 trials, the 11 in which
zero response has been observed could be considered as
having been conducted according to Gehan's design. With
this extremely optimistic interpretation, the proportion of
trials having used an identifiable statistical design rises to
25%.
Discussion
Gehan's design is simple and easy to understand. It is quite
satisfactory for trials that are not to be stopped when the
treatment is very effective. However, it tends to expose more
patients to an ineffective treatment, which may raise ethical
questions, particularly when treating a serious illness.
Gehan's method was published more than 30 years ago and
Design
Gehan
Fleming Two
Simon's
Minimax
Ensign
AN
33.8
69%
24.7
62%
,<2 >,7
,<6 ->-7
25.7
74%
22.5
9
22
45
=0
<,3
,<7
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>,8
,>8
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34%
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is still widely used with many phase II studies including 14
patients in the first stage. Nevertheless. the second stage is
rarely carried out. even when successes are observed during
the first stage. This may be because the sample sizes
suggested by Gehan's tables for the second stage are often
too large for phase II trials.
Fleming's design is recommended when one wants to
terminate the trial as soon as the effectiveness is considered to
have been demonstrated. It has the highest probability of
early termination under the efficacy hypothesis. In Fleming's
design. the total number of patients is estimated as if one was
planning a single-stage trial with the selected error rates.
Sample sizes for each stage are then selected arbitrarily. and
the decision-making rules are defined by the required values
for x and fi. In Simon's and Ensign's designs. on the other
hand. the sample size is not defined by the investigator. but
depends on the minimisation criterion.
In Simon's Optimum design. under the hypothesis of
treatment inefficacy. the probability of early termination of
the trial is large. and the average number of patients is
mimmum.
In the case of an extremely rare disease and thus a low
accrual rate. Simon's Minimax design will be preferred to the
Optimum design since it limits the maximum duration of the
study. For instance. with po=0.10. pi=0.30. x=0.10 and
f=0.10. Simon's Minimax design leads to a maximum of 25
patients under the efficacy hypothesis. Under the same
hypothesis. Simon's Optimum design leads to a maximum
of 35 patients. If the accrual rate is ten patients per year. this
difference could represent one extra year of accrual compared
with Simon's Minimax design.
One of the drawbacks of the two designs proposed by
Simon is that they do not allow the trial to be stopped early
when there is a long series of failures at the beginning. For
example. Simon's Optimum design for pc=0.20. pI=0.35.
x=0.10 and #=0.10 requires a sample size at the first stage
of n, =27 patients with early termination when five or fewer
successes have been observed. This implies stopping only
when at least 22 failures have been observed. even if the first
21 patients fail. Most investigators would want to stop a trial
with such poor results earlier. and this is the argument
underlying Ensign's design.
If it is likely that the treatment is ineffective. which may
often be the case in phase II trials in oncology. Ensign's
design is recommended since it allows for premature stopping
of the trial at the end of the first stage if no successes have
been observed among the first n1 patients. while preserving
the nominal :x and P errors.
When selecting the error probabilities. x and (3. the
investigator should be aware of their interpretations. The
type I error. x. is the probability of concluding wrongly that
the efficacy of a treatment justifies the undertaking of a phase
III trial. This error will lead to treating additional patients
with an ineffective treatment. and wasting addition funds. To
limit these risks. one would select a small value for :x. The
type II error. fi. is the probability of concluding that the
treatment is inefficient when in fact it is efficient. The plan to
undertake a phase III trial would then be abandoned in this
case. This error saves money but misses the chance to study a
potentially useful treatment. It is often considered as less
important an error than x. Should this not be the case. one
can select a small value for fi. In general the design with more
patients during the first stage is preferable since the
corresponding ,B error rate is small. The probability of
falsely concluding the treatment to be ineffective at the end of
the first stage will therefore be low.
It should be noted that phase II trials in cancer use
response as the outcome. whereas phase III trials use time to
recurrence or time to death. There may not be a strong
association between tumour response and patient survival.
Phase III trials are therefore essential for studying the
potential benefit in terms of surVival and disease-free survival.
Many trial protocols and most published reports of phase
II studies do not mention the design used. Statistical
considerations should be part of every phase II trial
protocol. These statistical considerations should include a
short description of the design with a reference. a justification
of the choice of design. and the values of the parameters
selected. The report of a phase II study should include this
information. but it should also present a description of the
type and duration of the responses. and a description of
toxicity. All these elements will contribute to the decision to
undertake a phase III trial.
Bullet points
The protocol of a phase II trial should include statistical
considerations including:
(1) a definition of the end points defining success:
(2) the name of the design used and a reference to a
published description of the method:
(3) the success rate po below which one wants to reject the
treatment:
(4) .. the probability of a conclusion in favour of efficacy
when the rate of success is po or less:
(5) The success rate Pi above which one wants to accept the
treatment:
(6) /3. the probability of a conclusion of inefficacy when the
level of efficacy is above P,
Publications reporting the results of a phase II trial should
include the same information. It should also present the
observed success rate with its confidence interval.
Acknowledgements
We thank Laurent Vabre for his assistance with the literature
review, and the referees for their constructive comments.
References
ENSIGN LG. GEHAN EA. KAMEN DS AND THALL P. (1994). An
optimal three-stage design for phase II clinical trials. Stat. Med..
13, 1727- 1736.
FLEMING TR. (1982). One sample multiple testing procedure for
phase II clinical trials. Biometrics. 38, 143- 151.
GEHAN EA. (1961). The determination of the number of patients
required in a preliminary and a follow-up trial of a new
chemotherapy agent. J. Chron. Dis.. 13, 346-353.
MACHINN D. CAMPBELL MJ. FAYERS PM AN-D PINOL A. (1996).
Sample size tables for clinical studies. Blackwell Scientific
Publications: Oxford.
SIMON R. (1989). Optimal two-stage designs for phase II clinical
trials. Controlled Clin. Trials. 10, 1-10.